Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

8/4/2023: MIRA Pharmaceuticals, (MIRA) INTERVIEWED BY THE WALL STREET RESOURCE

Go there now

Company News

As of April 30, 2025 • 2:01 PM ET

Date/Time Source News Release
04/23/2025 08:00 AM EDT ACCESS Newswire MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation
04/16/2025 08:00 AM EDT ACCESS Newswire MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion
04/01/2025 08:00 AM EDT ACCESS Newswire MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain
03/24/2025 07:30 AM EDT ACCESS Newswire MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development
03/13/2025 08:00 AM EDT ACCESS Newswire MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain
03/04/2025 08:00 AM EST ACCESS Newswire MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain
12/19/2024 09:00 AM EST ACCESSWIRE MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development
12/10/2024 08:30 AM EST ACCESSWIRE MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End
11/20/2024 07:44 AM EST ACCESSWIRE MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
10/28/2024 07:30 AM EDT ACCESSWIRE MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
Page

Additional News

As of April 30, 2025 • 2:01 PM ET

Date/Time Source News Release
04/23/2025 10:29 AM EDT SeekingAlpha MIRA Pharmaceuticals reports positive in vitro drug release data for topical Ketamir-2
04/16/2025 12:30 PM EDT AllPennyStocks.com Pharmaceutical Stock Jumps After Key Trial Findings
04/16/2025 09:44 AM EDT 24/7 Market News Mobile Gaming Industry Report Supports Siyata Mobile Merger Target, Core Gaming, Meteoric Rise
04/06/2025 06:49 PM EDT KlickAnalytics MIRA - Historical Price Movements Surrounding Earnings
04/06/2025 06:44 PM EDT KlickAnalytics MIRA - Historical Earnings Price Analysis
03/24/2025 07:53 AM EDT SeekingAlpha MIRA Pharmaceuticals signs LOI to acquire SKNY Pharmaceuticals
11/27/2024 04:31 AM EST US Earnings Reports Expected earnings - MIRA Pharmaceuticals Inc.
10/30/2024 02:16 PM EDT 24/7 Market News The MoBot Report
09/19/2024 09:00 AM EDT News Direct MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025
09/18/2024 07:00 AM EDT ACCESSWIRE IA MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.